GlassScriptPhysician profile
Naomi Quillin
NPI 1306499371
$1,461.12
in general payments reported to CMS, 2019-2025
14 companies · $13.57 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $505 · 2021: $246 · 2022: $260 · 2023: $75.04 · 2024: $124 · 2025: $13.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $261.80 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $203.11 | 2019-2020 | |
| Allergan, INC. | $165.83 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $160.48 | 2021-2022 | |
| Ivantis, INC | $117.68 | 2020 | |
| Sun Pharmaceutical Industries INC. | $117.37 | 2020 | |
| Glaukos Corporation | $109.31 | 2024 | |
| Alcon Vision LLC | $88.61 | 2023-2025 | Eysuvis, Total30, Dailies Total1 |
| Ocular Therapeutix, INC. | $62.50 | 2020 | |
| Bausch & Lomb Americas INC. | $53.98 | 2022-2024 | Xiidra, Miebo |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Novartis Pharmaceuticals Corporation | $36.56 | 2020-2022 | |
| Sight Sciences, INC. | $31.78 | 2020 | |
| Coopervision INC. | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naomi Quillin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.